Analyst Price Targets — NTRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 5, 2026 2:28 pm | — | Guggenheim | $270.00 | $230.65 | TheFly | Natera price target raised to $270 from $230 at Guggenheim |
| December 22, 2025 11:58 am | — | Canaccord Genuity | $285.00 | $231.96 | TheFly | Natera price target raised to $285 from $260 at Canaccord |
| December 15, 2025 11:27 am | — | Wells Fargo | $205.00 | $231.88 | TheFly | Natera price target raised to $205 from $190 at Wells Fargo |
| December 15, 2025 10:56 am | — | Barclays | $270.00 | $231.88 | TheFly | Natera price target raised to $270 from $230 at Barclays |
| December 1, 2025 9:32 pm | — | Morgan Stanley | $265.00 | $234.25 | TheFly | Natera assumed with an Overweight at Morgan Stanley |
| November 18, 2025 2:33 pm | — | UBS | $280.00 | $213.65 | TheFly | Natera price target raised to $280 from $218 at UBS |
| October 27, 2025 12:46 pm | Navann Ty | BNP Paribas | $172.00 | $192.36 | TheFly | Natera upgraded to Neutral from Underperform at BNP Paribas Exane |
| September 22, 2025 9:35 am | Brandon Couillard | Wells Fargo | $175.00 | $181.11 | TheFly | Natera initiated with an Equal Weight at Wells Fargo |
| September 2, 2025 8:59 pm | Conor McNamara | RBC Capital | $268.00 | $169.34 | TheFly | Natera price target raised to $268 from $255 at RBC Capital |
| August 10, 2025 8:28 pm | Patrick Wood | Morgan Stanley | $195.00 | $151.95 | TheFly | Natera price target raised to $195 from $185 at Morgan Stanley |
Latest News for NTRA
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced it will present new data in genitourinary malignancies at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), taking place February 26-28, 2026. Across four oral presentations in muscle-invasive bladder cancer (MIBC), these data reinforce Signatera's…
Natera, Inc. (NASDAQ: NTRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eighteen analysts that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, thirteen have given a buy recommendation and one has given
Natera, Inc. (NTRA) Q4 2025 Earnings Call Transcript
Natera (NTRA) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of a loss of $0.46 per share. This compares to a loss of $0.41 per share a year ago.
The headline numbers for Natera (NTRA) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.